Results 151 to 160 of about 539,134 (347)

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Molecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou   +11 more
wiley   +1 more source

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients. [PDF]

Melanoma Res, 2023
Fortman D, Avellan MGP, Hurd D, Schwartz M, Dubner H, Hewitt C, Berton S, Ernst S, Rose A, Zarour HWH, Davar D.   +10 more
europepmc   +1 more source

Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma?

, 1969
Liping Chen, Chuan Li, Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jiayin Yang   +5 more
openalex   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection. [PDF]

Front Immunol, 2022
Krummey SM, Gareau AJ.
europepmc   +1 more source

HUMAN RENAL TRANSPLANTATION WITH DONOR SELECTION BY LEUKOCYTE TYPING

, 1967
D. L. Stickel, D. Bernard Amos, Chester M. Zmijewski, James F. Glenn, R. R. Robinson   +4 more
openalex   +1 more source

Oocyte donor screening: the selection process [PDF]

, 2000
Lisa K. Johnson, K.A. Burry, Phillip E. Patton, P.A Acker, Marsha J. Gorrill   +4 more
openalex   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

A Matching Strategy To Guide Donor Selection for Ulcerative Colitis in Fecal Microbiota Transplantation: Meta-Analysis and Analytic Hierarchy Process. [PDF]

Microbiol Spectr, 2023
Zhang B, Yang L, Ning H, Cao M, Chen Z, Chen Q, Lian G, Tang H, Wang Q, Wang J, Lin Z, Wen J, Liu Y, Xuan J, Li X, Lin A, He J, Zhang L, Hou X, Zeng Q, Xiao C.   +20 more
europepmc   +1 more source

ALPORT SYNDROME: RENAL TRANSPLANTATION AND DONOR SELECTION [PDF]

, 2000
Clifford E. Kashtan
openalex   +1 more source